相似文献
1
The brief negative symptom scale: psychometric properties.
Schizophr Bull. 2011 Mar;37(2):300-5. doi: 10.1093/schbul/sbq059. Epub 2010 Jun 17.
2
The Brief Negative Symptom Scale (BNSS): Independent validation in a large sample of Italian patients with schizophrenia.
Eur Psychiatry. 2015 Jul;30(5):641-7. doi: 10.1016/j.eurpsy.2015.01.014. Epub 2015 Mar 8.
3
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale.
Schizophr Res. 2012 Dec;142(1-3):88-92. doi: 10.1016/j.schres.2012.10.012. Epub 2012 Nov 3.
4
The brief negative symptom scale in translation: A review of psychometric properties and beyond.
Eur Neuropsychopharmacol. 2020 Apr;33:36-44. doi: 10.1016/j.euroneuro.2020.01.018. Epub 2020 Feb 18.
5
Validation of the Brief Negative Symptom Scale and its association with functioning.
Schizophr Res. 2019 Jun;208:97-104. doi: 10.1016/j.schres.2019.04.005. Epub 2019 Apr 13.
6
Negative symptoms in bipolar disorder and schizophrenia: A psychometric evaluation of the brief negative symptom scale across diagnostic categories.
Schizophr Res. 2016 Feb;170(2-3):285-9. doi: 10.1016/j.schres.2015.12.014. Epub 2015 Dec 29.
7
A Psychometric Comparison of the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale.
Schizophr Bull. 2016 Nov;42(6):1384-1394. doi: 10.1093/schbul/sbw046. Epub 2016 May 12.
8
Polish version of the Brief Negative Symptom Scale (BNSS).
Psychiatr Pol. 2019 Jun 30;53(3):541-549. doi: 10.12740/PP/OnlineFirst/91490.
9
Polish version of the Self-evaluation of Negative Symptoms (SNS).
Psychiatr Pol. 2019 Jun 30;53(3):551-559. doi: 10.12740/PP/OnlineFirst/97352.
10
Spanish adaptation and validation of the Brief Negative Symptoms Scale.
Compr Psychiatry. 2014 Oct;55(7):1726-9. doi: 10.1016/j.comppsych.2014.05.024. Epub 2014 Jun 7.
引用本文的文献
1
The role of low subcortical iron, white matter myelin, and oligodendrocytes in schizophrenia: a quantitative susceptibility mapping and diffusion tensor imaging study.
Mol Psychiatry. 2025 Sep 5. doi: 10.1038/s41380-025-03195-7.
2
Blood and neuronal extracellular vesicle mitochondrial disruptions in schizophrenia.
Neuropsychopharmacology. 2025 Aug 23. doi: 10.1038/s41386-025-02204-1.
3
Acceptance and commitment therapy applied to early psychosis: Therapeutic foundations and a narrative systematic review.
World J Psychiatry. 2025 Aug 19;15(8):107313. doi: 10.5498/wjp.v15.i8.107313.
4
Using the grip strength effort task to measure reward processing dysfunction in schizophrenia and major depressive disorder.
Neurosci Appl. 2025 Jul 30;4:105524. doi: 10.1016/j.nsa.2025.105524. eCollection 2025.
5
The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trial.
Psychopharmacology (Berl). 2025 Aug 16. doi: 10.1007/s00213-025-06884-x.
6
Validation of the Romanian version of the brief negative symptom scale in a heterogeneous schizophrenia inpatient sample.
Glob Ment Health (Camb). 2025 Jul 17;12:e85. doi: 10.1017/gmh.2025.10037. eCollection 2025.
7
Anhedonia and Negative Symptoms in First-Episode Psychosis: A Systematic Review and Meta-Analysis of Prevalence, Mechanisms, and Clinical Implications.
Healthcare (Basel). 2025 Jul 24;13(15):1796. doi: 10.3390/healthcare13151796.
8
The role of mindfulness training supported by virtual reality in the nonpharmacological treatment of schizophrenia-research design.
Ann Gen Psychiatry. 2025 Aug 13;24(1):49. doi: 10.1186/s12991-025-00587-5.
9
Virtual reality-based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: a randomized controlled trial.
Nat Med. 2025 Aug 13. doi: 10.1038/s41591-025-03880-8.
10
The CARE project - study protocol and pilot results from the Polish population.
Front Psychiatry. 2025 Jul 23;16:1643722. doi: 10.3389/fpsyt.2025.1643722. eCollection 2025.
本文引用的文献
1
Anticipatory and consummatory components of the experience of pleasure in schizophrenia: cross-cultural validation and extension.
Psychiatry Res. 2010 Jan 30;175(1-2):181-3. doi: 10.1016/j.psychres.2009.01.020. Epub 2009 Dec 5.
2
Differences in glucose tolerance between deficit and nondeficit schizophrenia.
Schizophr Res. 2009 Feb;107(2-3):122-7. doi: 10.1016/j.schres.2008.09.023. Epub 2008 Nov 28.
3
Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese origin.
Psychiatry Res. 2008 Mar 15;158(2):195-205. doi: 10.1016/j.psychres.2006.09.007. Epub 2008 Feb 19.
4
Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure.
Schizophr Res. 2007 Jul;93(1-3):253-60. doi: 10.1016/j.schres.2007.03.008. Epub 2007 May 9.
5
Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status.
Schizophr Res. 2006 Jul;85(1-3):12-9. doi: 10.1016/j.schres.2006.03.002. Epub 2006 Apr 19.
6
The NIMH-MATRICS consensus statement on negative symptoms.
Schizophr Bull. 2006 Apr;32(2):214-9. doi: 10.1093/schbul/sbj053. Epub 2006 Feb 15.
7
The structure of negative symptoms within schizophrenia: implications for assessment.
Schizophr Bull. 2006 Apr;32(2):238-45. doi: 10.1093/schbul/sbj013. Epub 2005 Oct 27.
8
Deficit schizophrenia: association with serum antibodies to cytomegalovirus.
Schizophr Bull. 2006 Apr;32(2):396-400. doi: 10.1093/schbul/sbi054. Epub 2005 Sep 15.
9
Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim.
Schizophr Bull. 2006 Apr;32(2):220-2. doi: 10.1093/schbul/sbi039. Epub 2005 Aug 3.
10
Summer birth and deficit schizophrenia: a pooled analysis from 6 countries.
Arch Gen Psychiatry. 2004 Oct;61(10):985-9. doi: 10.1001/archpsyc.61.10.985.
Zotero 插件